Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Joelle Payne Straehla · DANA-FARBER CANCER INST · 2024 · $1 — PROJECT SUMMARY Nanoparticle-based therapies have many potential advantages for treating cancer, but there are currently no clinical biomarkers to predict which patients are most likely to benefit from nanotherapeutics over conventional anticancer agents. To improve the efficacy of nanoparticles for…
VALERIE B GOUON-EVANS · BOSTON MEDICAL CENTER · 2024 · $554,527 — PROJECT SUMMARY / ABSTRACT Liver disease affects hundreds of millions of people worldwide. Liver transplantation remains the only treatment for end stage liver disease (ESLD); however, transplantation faces a major burden due to a shortage of liver donors. The liver is known for a remarkable regener…
Ram I. Mahato · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2024 · $461,312 — PROJECT SUMMARY Medulloblastoma (MB) is the most common childhood brain tumor arising from the cerebellum. Many factors influence the proliferation, differentiation, and migration of cerebellar granular neuronal precursor (GNP). Among them, MDM2 is a major nexus between tumor suppressor TP53 and he…
DANIEL G ANDERSON · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $387,750 — Gene editing is a promising strategy for treating or even permanently curing genetic diseases. In particular, a new technique called prime editing has the potential to make small targeted insertions, deletions, and substitutions with very high potential coverage of known disease- causing mutations, …
THOMAS H BUGGE · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · 2024 · $1,942,173 — Cellular orchestration of extracellular matrix degradation Background: Our Section has a long-standing interest in pathways of extracellular matrix (ECM) degradation and the pathological consequences of insufficient or excessive ECM turnover. Research accomplished: Identification of the mannose …
Jinjun Shi · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $518,820 — ABSTRACT The use of RNA technologies to specifically target genetic alterations in tumor cells has shown great potential of becoming a novel therapy modality for cancer treatment. Nevertheless, systemic delivery of RNA agents such as messenger RNA (mRNA) to tumor cells in vivo commonly faces multipl…
David J Mooney · BETH ISRAEL DEACONESS MEDICAL CENTER · 2024 · $774,435 — ABSTRACT Impaired wound healing is an alarming problem in diabetes, attributed to the development of over 750,000 diabetic foot ulcerations (DFU) and 70,000 lower extremity amputations per year in the USA. Single-cell RNA- sequencing (scRNASeq) analysis provides valuable insights into transcriptiona…
Richard Brian Meagher · UNIVERSITY OF GEORGIA · 2024 · $226,500 — DectiSomes are lipid nanoparticles carrying an anti-infective drug and coated with pathogen receptor that targets them to pathogenic cells. DectiSomes reduce the effective dose for inhibition and killing of pathogens by order(s) of magnitude relative to conventional drugs, potentially overcoming the…
Elena Aikawa · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $771,902 — Project Summary Anti-retroviral therapy (ART) has protected many HIV patients against the development of AIDS. HIV infection has become a treatable disease. Increased risk for atherosclerotic vascular diseases in long-term HIV survivors or people living with HIV (PLWH) with no detectable virus load,…
Asuka Eguchi · UNIVERSITY OF CALIFORNIA-IRVINE · 2024 · $157,516 — Project Summary/Abstract The long-term objective of this study is to develop gene therapies that treat Duchenne muscular dystrophy (DMD) cardiomyopathy. DMD cardiomyopathy, characterized by ventricular chamber enlargement and thinning of the ventricular wall, ultimately leads to heart failure. Patho…
Rebecca Sara Cook · VANDERBILT UNIVERSITY · 2024 · $522,993 — Cancer nano-formulations for delivery of small molecule drugs are limited by the ability to target only ~10% of the genome. RNAi molecules can, in theory, be designed against any gene of interest, but siRNA use in clinical oncology faces delivery barriers such as nuclease degradation, rapid renal cl…
Jill A Helms · STANFORD UNIVERSITY · 2024 · $699,324 — Project abstract Maintaining the junctional epithelium (JE) is of primary importance if preservation of the cementum, periodontal ligament (PDL), and alveolar bone is to be achieved. New insights into JE barrier functions came with our discovery of a Wnt- responsive stem cell niche in the JE. In thi…
Christopher Akinleye Alabi · CORNELL UNIVERSITY · 2024 · $316,226 — Project Summary This study seeks to advance heterobifunctional degraders that induce targeted protein degradation through the ubiquitin proteasome pathway. Typically, molecular degraders involve a ligand that recruits an E3 ubiquitin ligase and another that targets a protein of interest (POI), formi…
Renukaradhya Jayamurthy Gourapura · OHIO STATE UNIVERSITY · 2024 · $196,875 — Project Summary/Abstract HEV is an emerged zoonotic pathogen. It infects nearly 20 million people annually, resulting in approximately 70,000 deaths yearly (2). In the U.S. the virus is believed to be endemic to swine herds with the virus making its way into the commercial food supply (3, 4). Genoty…
Andre Elias Nel · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $479,283 — The use of nano-enabled chemotherapy to trigger an immune response to pancreatic ductal adenocarcinoma (PDAC) introduces a novel approach for overcoming robust barriers to immunotherapy, including poor immunogenicity, low neoantigen burden, stromal interference (“T-cell exclusion”), overexpression o…
Katja Michael · UNIVERSITY OF TEXAS EL PASO · 2024 · $174,151 — A novel gene-based immunotherapy inducing melanoma destruction In the U.S., nearly 100,000 new melanoma diagnoses and 8,000 deaths are expected in 2023. Despite the advent of immunotherapy, especially checkpoint inhibitor antibodies (Abs), advanced melanoma remains a progressive and incurable diseas…
Janine M LaSalle · UNIVERSITY OF CALIFORNIA AT DAVIS · 2024 · $670,005 — The human fetal brain consumes up to 60% of the body’s oxygen and energy consumption, despite making up ~13% of body mass. When the demand for oxygen in the placenta and developing brain exceeds its supply, hypoxia is induced, followed by changes to mitochondrial respiration, protein translation, an…
Suchismita Acharya · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2024 · $370,000 — Glaucoma is a neurodegenerative disease of the eye with an estimated prevalence of 80 million patients worldwide by 2020, at least 6 to 8 million becoming bilaterally blind. Elevated intraocular pressure (IOP) causing axonal degeneration of the optic nerve and progressive loss of retinal ganglion ce…
Ke Cheng · COLUMBIA UNIV NEW YORK MORNINGSIDE · 2024 · $646,621 — PROJECT SUMMARY Heart disease is the leading cause of death in the United States. About 875,000 Americans die from heart disease each year, of which 50-60% deaths are caused by coronary artery disease (CAD). CAD, the most common type of heart disease, can lead to heart attack and sudden death. Whil…
Olga Gursky · BOSTON UNIVERSITY MEDICAL CAMPUS · 2024 · $445,637 — Abstract Aberrant lipoprotein metabolism is a hallmark of obesity that affects >40% of Americans. Obesity and its com- plications, including type-2 diabetes (T2D), cardiovascular, amyloid and severe viral diseases, are the leading causes of premature death. The ultimate goal of this research is to …